PYC Therapeutics (ASX:PYC) Announces Q1 2025 Shareholder Update
PYC Therapeutics (ASX:PYC) extends cash runway to over $200m and advances polycystic kidney disease program in Q1 2025.
Category: ASX-PYC
PYC Therapeutics Limited
Latest News
Eagle Mountain Mining (ASX:EM2) Completes Rights Issue
Surefire Resources NL (ASX:SRN) Announces Q1 2025 Highlights
Future Battery Minerals (ASX:FBM) Identifies Key Gold Targets and Expands WA Landholdings
Australian Rare Earths Limited (ASX:AR3) Completes EL6678 Farm-In
PYC Therapeutics (ASX:PYC) Announces Q1 2025 Shareholder Update
Hot Chili Limited (ASX:HCH) Announces Costa Fuego PFS and Maiden Ore Reserve
Cynata Therapeutics Limited (ASX:CYP) Releases Q1 2025 Activity Report
Perpetual Resources (ASX:PEC) Announces High-Grade Assay Results and Upcoming Drill Campaign
Raiz Invest (ASX:RZI) Reports Q3 FY25 Business Update
Livium Ltd (ASX:LIT) Secures A$5.0M Recycling Agreement with Sell & Parker
The Hub of Australian Finance News